PERIODIC TREATMENT REGIMENS WITH INHALED STEROIDS IN ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY-DISEASE - IS IT POSSIBLE

被引:14
作者
VANSCHAYCK, CP [1 ]
VANDENBROEK, PJJA [1 ]
DENOTTER, JJ [1 ]
VANHERWAARDEN, CLA [1 ]
MOLEMA, J [1 ]
VANWEEL, C [1 ]
机构
[1] UNIV NIJMEGEN,LUNG CTR DEKKERSWALD,NIJMEGEN,NETHERLANDS
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1995年 / 274卷 / 02期
关键词
D O I
10.1001/jama.274.2.161
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To determine whether inhaled corticosteroids can be discontinued in the stable phase of asthma or chronic obstructive pulmonary disease (COPD) or if this therapy should be continued. Design.-Nonrandomized open uncontrolled 5-year trial. Setting.-Prospective study in general practice. Patients.-Forty-eight patients with steroid-dependent asthma or COPD who had shown a decline in forced expiratory volume in 1 second (FEV(1)) of at least 80 mt per year and at least one exacerbation per year during the first 2 years of bronchodilator treatment. Subjects were treated additionally with inhaled steroids for another 2 years and were finally given the option to stop using steroids. Sixteen patients were willing to stop using beclomethasone and were studied for another year. No recruitment bias took place in this consecutive sample in the fifth year of follow-up. Two of 16 patients developed carcinomas and dropped out. Interventions.-Two years of bronchodilator treatment alone (400 mu g of salbutamol or 40 mu g of ipratropium bromide four times daily), followed by 2 years of additional inhaled corticosteroid treatment (400 mu g of beclomethasone two times daily), and finally 1 year of bronchodilator treatment alone. Main Outcome Measures.-Decline in lung function (FEV(1)), change in bronchial hyperresponsiveness, indicated by a provocative concentration of histamine causing a 20% fall in FEV(1) (PC20), morning peak expiratory flow rate (PEFR), diurnal PEFR, week-to-week variation of PEFR, bronchial symptoms, and exacerbations. Results.-The course of FEV(1) during the year in which beclomethasone was discontinued was not significantly different when compared with the 2-year period of beclomethasone treatment. Neither did the course of PC20, morning PEFR, diurnal PEFR, symptom score, and exacerbation rate change. Only the week-to-week variation of the PEFR increased after discontinuing steroids. Conclusions.-Discontinuing inhaled steroids is possible in some patients with asthma or COPD after 2 years of regular treatment. This might indicate that for certain groups of patients with mild asthma or COPD, periodic treatment schedules with inhaled steroids is the treatment policy for the future.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 27 条
[1]   THE EFFECT OF INHALED CORTICOSTEROIDS ON THE MAXIMAL DEGREE OF AIRWAY NARROWING TO METHACHOLINE IN ASTHMATIC SUBJECTS [J].
BEL, EH ;
TIMMERS, MC ;
ZWINDERMAN, AH ;
DIJKMAN, JH ;
STERK, PJ .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 143 (01) :109-113
[2]   EVALUATION OF PEAK FLOW AND SYMPTOMS ONLY SELF MANAGEMENT PLANS FOR CONTROL OF ASTHMA IN GENERAL-PRACTICE [J].
CHARLTON, I ;
CHARLTON, G ;
BROOMFIELD, J ;
MULLEE, MA .
BRITISH MEDICAL JOURNAL, 1990, 301 (6765) :1355-1359
[3]   MUCOSAL INFLAMMATION IN ASTHMA [J].
DJUKANOVIC, R ;
ROCHE, WR ;
WILSON, JW ;
BEASLEY, CRW ;
TWENTYMAN, OP ;
HOWARTH, PH ;
HOLGATE, ST .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 142 (02) :434-457
[4]   SLOWING THE DETERIORATION OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY-DISEASE OBSERVED DURING BRONCHODILATOR THERAPY BY ADDING INHALED CORTICOSTEROIDS - A 4-YEAR PROSPECTIVE-STUDY [J].
DOMPELING, E ;
VANSCHAYCK, CP ;
VANGRUNSVEN, PM ;
VANHERWAARDEN, CLA ;
AKKERMANS, R ;
MOLEMA, J ;
FOLGERING, H ;
VANWEEL, C .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (10) :770-778
[5]   COMMUNITY-BASED ASTHMA CARE - TRIAL OF A CREDIT CARD ASTHMA SELF-MANAGEMENT PLAN [J].
DSOUZA, W ;
CRANE, J ;
BURGESS, C ;
TEKARU, H ;
FOX, C ;
HARPER, M ;
ROBSON, B ;
HOWDENCHAPMAN, P ;
CROSSLAND, L ;
WOODMAN, K ;
PEARCE, N ;
POMARE, E ;
BEASLEY, R .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (07) :1260-1265
[6]   EFFECTS OF REDUCING OR DISCONTINUING INHALED BUDESONIDE IN PATIENTS WITH MILD ASTHMA [J].
HAAHTELA, T ;
JARVINEN, M ;
KAVA, T ;
KIVIRANTA, K ;
KOSKINEN, S ;
LEHTONEN, K ;
NIKANDER, K ;
PERSSON, T ;
SELROOS, O ;
SOVIJARVI, A ;
STENIUSAARNIALA, B ;
SVAHN, T ;
TAMMIVAARA, R ;
LAITINEN, LA .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (11) :700-705
[7]   COMPARISON OF A BETA-2-AGONIST, TERBUTALINE, WITH AN INHALED CORTICOSTEROID, BUDESONIDE, IN NEWLY DETECTED ASTHMA [J].
HAAHTELA, T ;
JARVINEN, M ;
KAVA, T ;
KIVIRANTA, K ;
KOSKINEN, S ;
LEHTONEN, K ;
NIKANDER, K ;
PERSSON, T ;
REINIKAINEN, K ;
SELROOS, O ;
SOVIJARVI, A ;
STENIUSAARNIALA, B ;
SVAHN, T ;
TAMMIVAARA, R ;
LAITINEN, LA .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (06) :388-392
[8]   EFFECT OF PREDNISONE AND BECLOMETHASONE DIPROPRIONATE ON AIRWAY RESPONSIVENESS IN ASTHMA - A COMPARATIVE-STUDY [J].
JENKINS, CR ;
WOOLCOCK, AJ .
THORAX, 1988, 43 (05) :378-384
[9]   EFFECT OF LONG-TERM TREATMENT WITH AN INHALED CORTICOSTEROID (BUDESONIDE) ON AIRWAY HYPERRESPONSIVENESS AND CLINICAL ASTHMA IN NONSTEROID-DEPENDENT ASTHMATICS [J].
JUNIPER, EF ;
KLINE, PA ;
VANZIELEGHEM, MA ;
RAMSDALE, EH ;
OBYRNE, PM ;
HARGREAVE, FE .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 142 (04) :832-836
[10]   REDUCTION OF BUDESONIDE AFTER A YEAR OF INCREASED USE - A RANDOMIZED CONTROLLED TRIAL TO EVALUATE WHETHER IMPROVEMENTS IN AIRWAY RESPONSIVENESS AND CLINICAL ASTHMA ARE MAINTAINED [J].
JUNIPER, EF ;
KLINE, PA ;
VANZIELEGHEM, MA ;
HARGREAVE, FE .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1991, 87 (02) :483-489